Abstract
The use of neuromuscular blocking agents (NMBAs) early in the development of ARDS has been a strategy of interest for many years. The use of NMBAs with a concomitant deep sedation strategy can increase oxygenation and possibly decrease mortality when used in the early stages of ARDS. The mechanism by which this occurs is unclear but probably involves a combination of factors, such as improving patient-ventilator synchrony, decreasing oxygen consumption, and decreasing the systemic inflammatory response associated with ARDS. The use of NMBA and deep sedation for these patients is not without consequence. This discussion describes the rationale and evidence behind the use of NMBAs in the setting of ARDS.
Footnotes
- Correspondence: William E Hurford MD, Department of Anesthesiology, University of Cincinnati College of Medicine, PO Box 670531, 231 Albert Sabin Way, Cincinnati, OH 45267-0531. E-mail: bill.hurford{at}uchealth.com.
The authors have disclosed no conflict of interest.
Dr Hurford presented a version of this report at the 54th Respiratory Care Journal Conference on Respiratory Care Controversies III, held June 5 and 6, 2015, in St. Petersburg, Florida.
- Copyright © 2016 by Daedalus Enterprises
